Business Wire

Interactive Brokers Expands Tax Planning Suite with New Professional Tools

9.10.2025 16:00:00 CEST | Business Wire | Press Release

Share

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, has introduced enhancements to its professional tax planning toolkit with the launch of TaxPlanner, available through PortfolioAnalyst. Its new capabilities complement existing tax-lot matching and tax loss harvesting features, giving investors greater control over the tax implications of their investment activity.

With Tax Planner, users create personal tax profiles from inputs such as income from other sources, deductions, withholdings, and tax rates. Tax Planner uses the tax profile as well as activities from their Interactive Brokers accounts to help estimate tax bills and assist with tax planning throughout the year. Tax Planner is available through PortfolioAnalyst, Interactive Brokers’ comprehensive and free portfolio management solution. PortfolioAnalyst consolidates accounts across financial institutions, tracks account performance and activity, and provides a broad set of tools for analyzing an entire portfolio and planning for the future. In addition to Tax Planner, PortfolioAnalyst also includes Allocation Goals to monitor portfolio allocations, the Retirement Planner to build a personalized retirement plan, and the Budgeting Tool to create monthly and annual budgets. With PortfolioAnalyst, investors can easily develop an integrated investment and financial management plan.

“Our mission is to equip clients with tools that make managing investment performance, including tax outcomes, more efficient while maintaining the low costs and global market access that sets Interactive Brokers apart,” said Milan Galik, Chief Executive Officer at Interactive Brokers. “The new Tax Planner gives investors a higher degree of oversight over the tax implications of their trades.”

In addition to Tax Planner, Interactive Brokers continues to offer a suite of tax optimization tools, including tools that help clients identify losses across portfolios and match closing trades with specific lots post- or pre-trade. These features assist with tax loss harvesting by helping investors manage capital gains and losses.

Key Features of IBKR’s Professional Tax Planning Tools

Plan Ahead with Tax Planner

  • Combine investment income with other sources of taxable income
  • Choose which investment accounts to include
  • Customize tax rates to reflect personal circumstances
  • Estimate total year-end taxes across all income sources

Identify Tax Loss Opportunities Across Portfolios

  • Identify tax loss harvesting opportunities across the portfolio
  • View projected allowed and disallowed losses under wash-sale rules
  • Discover and purchase replacement securities using proceeds from closed positions

Tax Smart Trading

  • Preview potential short- or long-term gains or losses before submitting orders and select specific lots to close using the new Close Specific Lots tool
  • Review and adjust tax-lot matching after the trade and optimize realized short- and long-term gains and losses using Tax Optimizer
  • Choose from multiple tax-lot matching methods and set a default method to save time and automatically match trades

To learn more about how IBKR’s tax tools support strategic investing, visit:

US and countries served by IB LLC: Tax Reporting
Canada: Tax Reporting
UK: Tax Reporting
Europe: Tax Reporting
Australia: Tax Reporting
Hong Kong: Tax Reporting
Singapore: Tax Reporting

To explore the full capabilities of PortfolioAnalyst, visit: PortfolioAnalyst

The tax tools may not be suitable for tax residents of certain jurisdictions. Clients should consider consulting a tax advisor to determine their specific situation.

The best-informed investors choose Interactive Brokers

About Interactive Brokers Group, Inc.:

Interactive Brokers Group, Inc. (NASDAQ: IBKR) is a member of the S&P 500. Its affiliates provide automated trade execution and custody of securities, commodities, foreign exchange, and forecast contracts around the clock on over 160 markets in numerous countries and currencies from a single unified platform to clients worldwide. We serve individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation have enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Interactive Brokers has consistently earned recognition as a top broker, garnering multiple awards and accolades from respected industry sources such as Barron's, Investopedia, Stockbrokers.com, and many others.

Follow Interactive Brokers on social media:
US and World (except Europe): Facebook, Instagram, LinkedIn, X, YouTube, TikTok
UK and Europe: Facebook, Instagram, X, TikTok

View source version on businesswire.com: https://www.businesswire.com/news/home/20251009727482/en/

Contacts

Contacts for Interactive Brokers Group, Inc. Media: Katherine Ewert,
media@ibkr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye